Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EO2463 + rituximab
- Development stage
- Phase 2
- Lead developer
- Enterome
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
EO2463 + rituximab is a combination of a microbial-derived peptide therapeutic vaccine (EO2463) with rituximab, a monoclonal antibody targeting CD20. EO2463 is composed of four synthetically produced HLA-A2-restricted epitopes exhibiting molecular mimicry with B cell markers CD20, CD22, CD37, and CD268 (BAFF-receptor), plus a helper peptide derived from human telomerase reverse transcriptase (hTERT). The vaccine is designed to expand memory CD8+ T cells that cross-react with these B cell antigens, driving anti-tumor activity against B cell malignancies. Rituximab complements this approach through direct targeting and depletion of CD20+ B cells. This combination is under clinical investigation primarily for follicular lymphoma (FL) and marginal zone lymphoma (MZL) in phase 1/2 trials, aiming to enhance T cell and antibody-mediated anti-lymphoma effects. EO2463 is administered subcutaneously, while rituximab is given intravenously[1][3][5][7].
- Other names
- EO2463 + rituximab
02
Targets
CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)TNFRSF13C (B-cell Activating Factor Receptor)CD37TERT (Telomerase)
Beyond the preview
Go deeper on EO2463 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EO2463 + rituximab.